A new study from Colombia’s Universidad de Antioquia, published in the peer reviewed journal Medical Cannabis and Cannabinoids, highlights CBD-rich oil as a treatment option for neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD).

CBD oil.

In a two-year prospective study, researchers observed that a majority of patients experienced significant improvements in symptoms and a reduction in caregiver distress. This open-label study reveals that CBD oil could provide a safer, effective alternative for managing challenging AD symptoms, particularly for those with disease onset after age 65.

The study, titled Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease with a Cannabis-Based Magistral Formulation: An Open-Label Prospective Cohort Study, was conducted between July 2020 and July 2023 with researchers from Universidad de Antioquia and two research hospitals in Colombia. It aimed to evaluate the effectiveness and safety of CBD-rich oil in treating neuropsychiatric symptoms for Alzheimer’s patients, a common issue impacting both patients and their caregivers.
Continue reading

A study published in the peer reviewed journal Medical Cannabis and Cannabinoid and e-published by the National Library of Medicine reveals promising findings on the impact of high-THC marijuana on PTSD symptoms.

The real-world, observational study examined 58 UK civilians who had prior cannabis experience and a confirmed PTSD diagnosis, with data sourced from the T21 patient registry.

The research analyzed the effects of controlled inhalation of THC-rich cannabis flowers, focusing on changes in health-related quality of life (HRQoL), mood, anxiety, sleep, and PTSD-specific symptoms. Patients who met the inclusion criteria—having completed both baseline and three-month follow-up PROMs (patient-reported outcome measures) questionnaires—showed notable improvements in overall health, mood, and sleep quality at the three-month mark.
Continue reading

A new study highlights the potential of cannabis-derived compounds as effective agents against multidrug-resistant (MDR) bacterial infections.

The study is being published in the upcoming issue of the European Journal of Microbiology and Immunology, and it was published online ahead of print by the U.S. National Library of Medicine.

A study, published in Molecular Psychiatry, led by Professor Bernard Lerer from the Department of Psychiatry at the Hadassah—Hebrew University Medical Center shows promising results for using psilocybin as a potential treatment for obsessive-compulsive disorder (OCD) and Tourette’s syndrome.

Dried psilocybin.

The study, titled “Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming”, was published in the journal Molecular Psychiatry.

The study included 50 genetically modified mice that displayed excessive grooming and anxiety, similar to human OCD behaviors and head-body twitches similar to tics suffered by patients with Tourette’s syndrome.
Continue reading